
Ediz Dalkilic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1746661/publications.pdf Version: 2024-02-01



EDIZ DALKILIC

#	Article	IF	CITATIONS
1	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clinical Rheumatology, 2022, 41, 85-94.	2.2	4
2	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	3.0	0
3	PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology, 2021, 60, 1755-1762.	1.9	4
4	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
5	Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet's disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 1451-1459.	1.6	7
6	Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability. Clinical Rheumatology, 2021, 40, 3797-3805.	2.2	3
7	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
8	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. American Journal of Ophthalmology, 2021, 228, 58-64.	3.3	10
9	Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Advances in Rheumatology, 2021, 61, 55.	1.7	3
10	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
11	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	0
12	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	8
13	Rheumatology patients' attitude regarding Ramadan and fasting. International Journal of Rheumatic Diseases, 2020, 23, 1082-1087.	1.9	2
14	Current Smoking Is Increased in Axial Psoriatic Arthritis and Radiographic Sacroiliitis. Journal of Rheumatology, 2020, 47, 1354-1358.	2.0	6
15	A successful pregnancy in a patient with Takayasu's arteritis under tocilizumab treatment: A longitudinal case study. International Journal of Rheumatic Diseases, 2019, 22, 1941-1944.	1.9	8
16	Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. Rheumatology International, 2019, 39, 2159-2165.	3.0	7
17	Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis. PLoS Genetics, 2019, 15, e1008038.	3.5	41
18	What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?. Clinical and Experimental Rheumatology, 2019, 37, 808-812.	0.8	3

Ediz Dalkilic

#	Article	IF	CITATIONS
19	Methotrexate intoxication: Beyond the adverse events. International Journal of Rheumatic Diseases, 2018, 21, 1557-1562.	1.9	12
20	Patients' concerns regarding biological agents in rheumatology. International Journal of Rheumatic Diseases, 2018, 21, 1219-1226.	1.9	2
21	Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. Clinical Rheumatology, 2018, 37, 3443-3448.	2.2	24
22	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. Journal of Rheumatology, 2016, 43, 524-529.	2.0	67
23	Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. Journal of Rheumatology, 2015, 42, 1661-1666.	2.0	43
24	Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers. European Journal of Rheumatology, 2015, 2, 62-65.	0.6	3
25	Comparing femaleâ€based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. International Journal of Rheumatic Diseases, 2014, 17, 653-657.	1.9	14
26	The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Modern Rheumatology, 2013, 23, 525-528.	1.8	7
27	The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Modern Rheumatology, 2013, 23, 525-528.	1.8	5
28	Ki-67 proliferation index in renal biopsy samples of patients with systemic lupus erythematosus and its correlation with clinical findings. Iranian Journal of Kidney Diseases, 2013, 7, 198-203.	0.1	3
29	Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Modern Rheumatology, 2012, 22, 463-466.	1.8	5
30	Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Modern Rheumatology, 2012, 22, 738-742.	1.8	8
31	Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Modern Rheumatology, 2012, 22, 463-466.	1.8	4
32	Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Modern Rheumatology, 2012, 22, 738-742.	1.8	3